Amarin Corporation plc
Amarin Corporation plc develops and commercializes cardiovascular disease treatments in the US, Europe, Canada, Lebanon, and the UAE. They offer VASCEPA, a prescription omega-3 fatty acid product for triglyceride reduction. Products are sold primarily to wholesalers and specialty pharmacies. The company has a collaboration with Mochida Pharmaceutical Co., Ltd. Amarin was formerly known as Ethical Holdings plc and is headquartered in Dublin, Ireland.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- Price to book ratio (10.85) is significantly higher than the sector mean (8.32).
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (16.32%).
- EV/EBITDA (100.00) is significantly higher than the sector mean (21.51).
- EV/EBIT (100.00) is significantly higher than the sector mean.
- The Price to Free Cash Flow ratio (100.00) is significantly higher than the sector mean.
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 1.5 |